• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Charles River Laboratories International Inc.

Virpax reports positive non-human study results for topical spray film that treats chronic pain

December 8, 2021 By Sean Whooley

Virpax Pharmaceuticals (NSDQ:VRPX) today reported positive results from a study of its Epoladerm treatment for chronic pain management. Berwyn, Pennsylvania-based Virpax designed Epoladerm, one of its lead investigational products, for managing pain associated with osteoarthritis of the knee. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pain Management, Pharmaceutical Tagged With: Charles River Laboratories International Inc., Virpax Pharmaceuticals

Charles River Labs shuffles the deck | Personnel Moves

August 24, 2011 By MassDevice staff Leave a Comment

Charles River Labs

Charles River Laboratories International Inc. (NYSE:CRL)  announced this week that its research models and preclinical services, hand in hand with shuffling its executive deck to drive growth.

Filed Under: News Well Tagged With: Charles River Laboratories International Inc., Corpak Medsystems Inc., Personnel Moves, Relievant Medsystems Inc., Zynex Inc.

Henry Schein Q1 profits rise 26 percent on healthy bump in sales | Earnings roundup

May 4, 2011 By MassDevice staff Leave a Comment

MassDevice.com Earnings Roundup

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: CardioNet Inc., Charles River Laboratories International Inc., Cynosure Inc., Dexcom, Exactech Inc., Genomic Health Inc., Henry Schein Inc., IntriCon Corp., Masimo, McKesson Corp., Q1, Solta Medical Inc., STAAR Surgical Co, Thoratec Corp.

CardioFocus reels in $14 million | Funding roundup

February 25, 2011 By MassDevice staff Leave a Comment

M and A Roundup

CardioFocus Inc. drummed up in nearly $14 million in a hoped-for $15.6 million funding round.

The Marlborough, Mass.-based company is developing a visually guided balloon catheter that uses a rotating laser to ablate the tissue surrounding the pulmonary artery’s entrance into the heart. The technology is intended to reduce atrial fibrillation.

Filed Under: News Well Tagged With: Cardiofocus, Charles River Laboratories International Inc., PLC Systems Inc.

Sigma-Aldrich profits edge upwards after slight sales uptick | Earnings roundup

February 10, 2011 By MassDevice staff Leave a Comment

MassDevice.com Earnings Roundup

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple day:

Filed Under: Business/Financial News, MassDevice Earnings Roundup, News Well Tagged With: Charles River Laboratories International Inc., Clinical Data Inc., Misonix, pSivida Corp., Sigma-Aldrich Corp.

Charles River Labs looks to trim the fat

December 15, 2010 By MassDevice staff Leave a Comment

CRL logo

Charles River Laboratories International Inc. (NYSE:CRL) launched a cost-cutting plan to raise value for its shareholders.

The Wilmington, Mass.-based contract research organization is planning to sell off certain clinical assets and raised its guidance for 2010.

Filed Under: Business/Financial News, News Well, Research & Development Tagged With: Charles River Laboratories International Inc.

Transposagen licenses Charles River rats

October 17, 2010 By MassDevice staff Leave a Comment

CRL, Transposagen logos

Transposagen Biopharmaceuticals Inc. signed an exclusive licensing deal with Charles River Laboratories International Inc. (NYSE:CRL) for lab rats.

Under the agreement, Wilmington, Mass.-based Charles River will market and distribute the Lexington, Ky.-based lab rat developer’s p53 and Bcrp TGEM Knockout rat models, so named for mutations in their p53 and Bcrp genes.

Filed Under: Business/Financial News, Lab Instruments & Supplies, News Well, Research & Development Tagged With: Charles River Laboratories International Inc., Transposagen Biopharmaceuticals Inc.

Charles River Labs accelerates stock buyback, inks $750M credit agreement

August 27, 2010 By MassDevice staff Leave a Comment

CRL logo

Charles River Laboratories International Inc. (NYSE:CRL), fresh from the collapse of a proposed, $1.6 billion merger with WuXi PharmaTech (Cayman) Inc. (NYSE:WX), plans to accelerate a $300 million stock buyback and took out a $750 million credit line.

The Wilmington, Mass.-based contract research organization said the repurchasing plan will see it buy back 6 million shares initially, with the final number to be determined based on a discounted price based on its daily volume-weighted average price during a a six-month-or-less period as determined by Morgan Stanley & Co. Inc., which is brokering the buyback.

Filed Under: Business/Financial News, News Well, Research & Development Tagged With: Charles River Laboratories International Inc.

Another tough quarter for Charles River Labs

August 4, 2010 By MassDevice staff Leave a Comment

CRL logo

The second quarter at Charles River Laboratories International Inc. (NYSE:CRL) was by all accounts disappointing and things may only get worse.

The clinical research organization on Monday said net income during the three months ended June 30 was $14.5 million, down from a $34.2 million profit during the same quarter last year. Revenues also fell, sliding 5.2 percent to $292.1 million. Revenues in the company’s pre-clinical segment fell $17.5 million to $125 million, more than overwhelming a $2 million rise for the research models and services division.

Filed Under: Biotech, Business/Financial News, MassDevice Earnings Roundup, News Well, Research & Development Tagged With: Charles River Laboratories International Inc.

CRL spikes $1.6 billion WuXi merger over shareholder concerns

July 30, 2010 By MassDevice staff Leave a Comment

CRL logo

Charles River Laboratories International Inc. (NYSE:CRL) will leave WuXi PharmaTech (Cayman) Inc. (NYSE:WX) at the altar and take its $1.6 billion dowry with it, after failing to convince shareholders that the union was in the best interest of the company.

The Wilmington, Mass.-based contract research organization said it has agreed to terminate the proposed deal and will pay a $30 million break-up fee.

Filed Under: Business/Financial News, News Well, Research & Development Tagged With: Charles River Laboratories International Inc.

Second proxy advisory firm backs Charles River Labs/WuXi merger

July 28, 2010 By MassDevice staff Leave a Comment

CRL, WX logos

Another proxy advisory firm is backing the proposed, $1.6 billion merger between WuXi PharmaTech (Cayman) Inc. (NYSE:WX) and Charles River Laboratories International Inc. (NYSE:CRL), which has drawn opposition from some of CRL’s top investors.

RiskMetrics Group’s ISS Proxy Advisory Services recommended that WuXi shareholders vote for the acquisition of WuXi.

Filed Under: Business/Financial News, Mergers & Acquisitions, News Well, Research & Development Tagged With: Charles River Laboratories International Inc., WuXi PharmaTech (Cayman) Inc.

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS